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Background: The link between guideline adherence and outcomes is a highly demanded issue 
in diabetes care. We aimed to assess the adherence to guidelines and its impact on hospitalization 
using a simple set of performance measures among patients with diabetes.
Methods: We performed a retrospective cohort study, using health care claims data for adult 
patients with treated diabetes (2011–2013). Patients were categorized into three drug treatment 
groups (with oral antidiabetic agents [OAs] only, in combination with insulin, and insulin only). 
Performance measures were based on international established guidelines for diabetes care. 
Multivariate logistic regression models predicted the probability of hospitalization (2013) by 
adherence level (2011) among all treatment groups.
Results: A total of 40,285 patients with diabetes were enrolled in 2011. Guideline adherence 
was quite low: about 70% of all patients received a biannual hemoglobin A
1c
 measurement 
and 19.8% had undergone an annual low-density lipoprotein cholesterol test. Only 4.8% were 
exposed to full adherence including all performance measures (OAs: 3.7%; insulin: 7.7%; and in 
combination: 7.2%). Increased guideline adherence was associated with decreased probability of 
hospitalization. This effect was strongest in patients using OAs and insulin in combination.
Conclusion: Our study showed that measures to reflect physicians’ guideline adherence in 
diabetes care can easily be calculated based on already available datasets. Furthermore, these 
measures are clearly linked with the probability of hospitalization suggesting that a better 
guideline adherence by physicians could help to prevent a large number of hospitalizations.
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Introduction
The link between guideline adherence, in terms of performed process measures, and 
clinical outcomes is a highly demanded issue in diabetes care. Diabetes is one of the 
leading health problems in the 21st century and requires continuous medical care, 
patients’ self-management, and risk reduction strategies.1–3 Several multidisciplinary 
expert committees, including the American Diabetes Associations, the European Society 
of Cardiology, and the European Association for the Study of Diabetes, report and 
adapt annually clinical guidelines to improve diabetes outcomes.3,4 In view of the big 
discussion on how to measure guideline adherence, evidence suggests that intermediate 
outcomes such as hemoglobin A
1c
 (HbA
1c
) can be improved and complications of 
diabetes can be reduced by controlling for even a simple set of performance measures 
such as HbA
1c
, blood pressure, and low-density lipoprotein (LDL) cholesterol.5–8 
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However, only few data exist on the adherence to guidelines 
and its effect on further important clinical outcomes. While 
studies have shown that the adherence to guidelines has a 
positive impact on all-cause mortality, the effect on the risk 
of hospitalization has not been well studied.9,10 One study 
found an association between the adherence to screening 
guidelines and the hospitalization for complications with 
diabetes using an outdated (1994–1999) and limited sample 
of Medicare enrollees aged over 65 years.11 Another study 
with diabetes patients living in a city of north-west Italy and 
aged 36–80 years showed that adherence was associated 
with reduced hospitalizations.12 Thus, it is not clear how 
the performance of the most important process measures 
in diabetes care affects the risk of hospitalization in a large 
population of elderly and nonelderly patients with diabetes. 
Furthermore, we assume that it is crucial to differentiate 
the patients according to drug treatment, since physicians’ 
awareness and therefore guideline adherence increased with 
therapy intensity. Therefore, the purpose of this study was 
to examine the adherence to established diabetes guidelines 
using a set of simple performance measures at individual 
patient level, and its impact on subsequent hospitalization by 
differentiating patients by drug treatment. To do so, we used 
health care claims data for retrospective cohort reflecting a 
large population with diabetes.
Materials and methods
Study design and study population
This study was based on health care claims data from a large 
health insurance group in Switzerland (Helsana) covering 
about 1.2 million residents with mandatory health insur-
ance. Claims files contained information on the enrollees’ 
age, sex, health insurance plan, date of hospitalization, and 
prescribed drugs including the ingredients as defined by the 
Anatomical Therapeutic Chemical (ATC) code from the 
World Health Organization.13 The health insurance plan was 
characterized by the choice of a managed care model and 
the chosen deductible class. As managed care models, we 
defined health plans with capitation, family doctor models, 
or telemedicine models. Deductibles are compulsory for all 
Swiss residents and range from Swiss Francs (CHF) 300 to 
CHF 2,500 per year. The standard deductible is CHF 300, 
but insured persons can choose a higher deductible (CHF 
500, 1,500, 2,000, and 2,500) in exchange for reduced pre-
miums. We performed a retrospective cohort study includ-
ing all adult persons who were identified as patients with 
diabetes mellitus, continuously insured, and alive between 
2011 (baseline) and 2013 (follow-up). In order to display 
the temporal sequence of adherence and hospitalization, we 
determined patients’ guideline adherence by including all 
eligible patients with diabetes between January 1, 2011 and 
December 31, 2011, and estimated patients’ future hospital-
ization risk on the basis of patients who were still eligible 
between January 1, 2013 and December 31, 2013. According 
to the national ethical and legal regulation, an ethical approval 
was not needed. A written informed patient consent was also 
not obtained for this study.
Identification of patients with diabetes
Treated patients were classified as all persons with at least 
one drug item for diabetes (oral blood glucose-lowering 
drug [ATC code A10B] or insulin [ATC code A10A]) in 
the baseline year. According to their drug treatment, we dif-
ferentiated patients with insulin-dependent from those with 
noninsulin-dependent diabetes by dividing the sample into 
three groups: 1) patients using oral antidiabetic agents (OAs), 
2) patients using insulin, and 3) patients using OAs and 
insulin in combination. Additionally, we considered patients’ 
drug treatment with antihypertensives (ATC code C02/C07/
C08/C09) and lipid-lowering agents (ATC code C10) as an 
indicator for the occurrence of the typical comorbid chronic 
conditions “hypertension” and “hyperlipidemia”.
Definition of adherence to guidelines
Extracted from the American Diabetes Association recom-
mendations, we identified a set of performance measures 
reflecting the adherence to guidelines in diabetes care. The 
set of four performance measures included the frequency of 
HbA
1c
 measurements, lipid profile (total cholesterol and/or 
high-density lipoprotein and/or LDL cholesterol and triglyc-
erides), nephropathy status (serum creatinine, albuminuria), 
and measurement and the frequency of ophthalmologist 
visits.3 Testing the HbA
1c
 was seen as suitable if at least two 
measurements per patient were performed in 2011, while 
the other performance measures were defined as adequate if 
at least one measurement or consultation were conducted in 
2011. Good diabetes care in terms of good guideline adher-
ence was seen when all criteria were fulfilled simultaneously. 
However, to give an insight on how the distribution of the 
(non)adherent patients looks, the different criteria were 
broken down into a total of five adherence levels. Thus, a 
hierarchical model of adherence to guidelines was developed 
by assigning each performance measure stepwise to an adher-
ence level. The five adherence levels were defined as follows: 
level 0 was defined as “nonadherent”, level 1 included “at 
least two measurements of HbA
1c
”, level 2 contained “level 1 
and lipid profile”, level 3 included “level 2 and nephropathy 
status”, and level 4 was defined as “receiving all performance 
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measures including ophthalmologist visits” (Figure 1). 
Thereby a biannual HbA
1c
 measurement was defined as the 
minimal criterion for guideline adherence. HbA
1c
 testing is 
the most commonly used measure and preferred standard to 
monitor glycemic control and represents an indicator to pre-
dict complications in patients with diabetes. Consequently, 
we began with level 0 defined as no or only one HbA
1c
 test 
per year and no other measurement.
statistical analysis and outcome
We used descriptive statistics to characterize the patient 
group and to examine the performed process measures and 
the occurrence of hospitalization at baseline. The outcome 
of interest was all-cause hospitalization in 2013 (follow-up), 
defined as an overnight hospital stay or a hospital stay of 
at least 24 hours within the given year. The proportion of 
patients, who were hospitalized at follow-up, was calculated 
for each adherence level. We used chi-square tests to com-
pare the differences in the proportions of patients between 
the three drug treatment groups (OAs, insulin, and OAs and 
insulin in combination). To predict the probability of hospital-
ization at follow-up (2013) by the adherence levels of patients 
with diabetes at baseline (2011), we calculated adjusted odds 
ratios (OR) and 95% confidence intervals (CI) using multi-
variate logistic regression models. Regression analyses were 
controlled for age, sex, health insurance status, hospitalization 
in 2011, drug treatment group, drugs used for the treatment of 
comorbid hypertension and hyperlipidemia, and included an 
interaction term between adherence level and drug treatment 
group. The ORs of hospitalization as function of adherence 
level for the different treatment groups were displayed in a 
figure. Therefore, we performed two models including the 
same variables, the first one with adherence in its original 
scale (as factor) and the second one with adherence treated as 
interval scaled variable to display the log-linear associations 
by treatment group. We calculated the effect of adherence 
levels for the three treatment groups as well as the pairwise 
differences. P-values for all regression model results were 
calculated with adjustment for multiple comparisons. Data 
were analyzed using R, version 3.0.1 (R Foundation for 
Statistical Computing, Vienna, Austria), multiple testing was 
performed with the supplementary package “multcomp” for 
multiple testing applying the default comparison procedure.14 
P,0.05 was taken to indicate statistical significance.
Results
Patient characteristics
Of the 40,285 patients included in this cohort, most were 
males (55.1%), over 60 years (74.8%), had a low deductible 
class (95.4%), and were not enrolled in a managed care 
Figure 1 Classification of adherence levels.
Note: The adherence levels were measured per patient in 2011.
Abbreviations: hba1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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model (69.8%; Table 1). Almost 77% received at least one 
prescription for antihypertensive drugs and 52.4% received 
a lipid-lowering agent. Overall, 70.5% were classified as 
treated with OAs, 12.3% with insulin, and 17.2% with OAs 
and insulin in combination. In every patient group, about 
three-quarters of patients were aged 60 years and older, with 
exception of insulin-treated patients who had a significantly 
higher proportion of those aged under 60 years (41.1%; 
P,0.001). The hospitalization rate at follow-up (2013) was 
lower in patients using OAs than in patients using insulin 
and in those using OAs and insulin in combination (26.5% 
vs 31.7% and 31.5%, respectively; P,0.001).
Performance measures and adherence to 
guidelines
The percentages of patients with performed process measures 
in diabetes care are reported in Table 2. About 88% of all 
patients had at least one annual HbA
1c
 measurement. While 
59.0% of patients had an assessment of the lipid profile, 
only 19.8% had undergone a LDL cholesterol test. More 
than three-quarters of patients had a serum creatinine test, 
13.1% had undergone an albuminuria test, and only 12.0% 
had both nephropathy measurements, and 44.2% visited an 
ophthalmologist. With exception of the LDL cholesterol test, 
statistically significant differences between the different drug 
treatment groups were found for all performance measures. 
Almost 92% of patients treated with OAs and insulin in 
combination had at least one annual HbA
1c
 measurement, 
whereas only 86.6% of patients using OAs received this pro-
cess measure. Furthermore, the proportion of patients visiting 
an ophthalmologist differs substantially between the patient 
group “OAs” with 41.2% and the groups “insulin” and “OAs 
and insulin in combination” with about 52%.
Approximately 30% of all patients with diabetes were 
exposed to nonadherence (level 0). In 24.0% of patients, 
HbA
1c
 was measured twice a year (level 1). The highest 
proportion of patients exposed to nonadherence was found 
at level 2 including at least two HbA
1c
 measurements in a 
year and an annual lipid profile (37.0%). About 4% had in 
addition to level 2 a yearly nephropathy status (level 3) and 
only 4.8% were exposed to the full adherence level (level 4), 
which additionally comprised an annual ophthalmologist 
visit. Patients treated with OAs were the group with the high-
est percentage of patients exposed to nonadherence (OAs: 
32.9% vs insulin: 27.0% and OAs and insulin in combination: 
20.1%; P,0.001). Compared with patients treated with OAs 
and those with OAs and insulin combined, insulin users had 
the highest proportion of patients exposed to full adherence 
(level 4; insulin: 7.7% vs OAs: 3.7% and OAs and insulin 
in combination: 7.2%; P,0.001).
adherence and subsequent hospitalization
Table 3 shows the proportion of patients exposed to (non)
adherence in 2011 with a hospitalization in 2013. Almost 
Table 1 Patients characteristics of the diabetes cohort by drug treatment group at baseline
Characteristic Total
n=40,285
Users of OAs
n=28,404
Users of insulin
n=4,965
Users of OAs and insulin in combination
n=6,916
P-valuea
% % % %
Population characteristics and hospitalization (2011)
Sociodemographics
Male 55.1 54.6 55.4 56.7 0.005
Age group (years) ,0.001
18–39 2.9 1.3 14.0 1.9
40–59 22.3 21.0 27.1 23.7
60–79 58.2 60.4 42.5 60.6
.79 16.6 17.3 16.4 13.8
health insurance status
Managed care model 30.2 31.7 25.9 27.0 ,0.001
Deductible ,0.001
High (.CHF 500) 4.6 5.3 2.6 3.0
Low (CHF 300/500) 95.4 94.7 97.4 97.1
hospitalization 23.4 20.5 29.4 30.9 ,0.001
Use of antihypertensive drugs 76.5 77.0 63.9 83.5 ,0.001
Use of lipid-lowering drugs 52.4 51.1 45.0 62.8 ,0.001
Hospitalization (2013) 25.9 26.5 31.7 31.5 ,0.001
Note: aP-values refer to chi-square test across the three drug treatment groups.
Abbreviations: CHF, Swiss Francs; OAs, oral antidiabetic agents.
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one-third of the hospitalized patients were exposed to non-
adherence and about 7% of the patients with hospitalization 
had at least an adherence level of 3. Of the patients exposed 
to nonadherence, 28.2% were hospitalized, whereas only 
19.4% of the full adherent persons (level 4) had a hospital stay 
(results not shown). The proportion of hospitalized patients 
using OAs and those using insulin decreased significantly 
with the adherence levels from over 30% (OAs: 35.3%; 
insulin: 32.2%) among the patients exposed to nonadherence 
to 2.8% (OAs) and 5.7% (insulin), respectively among the 
patients exposed to full adherence (level 4; P,0.001).
The ORs of hospitalization in 2013 as a function of 
adherence level in 2011 for the different treatment groups, 
including the interaction term “adherence level-drug treat-
ment group” and adjusted for multiple testing, are shown in 
Table 4 and Figure 2. The interaction term was statistically 
significant (P=0.02; result not shown). Table 5 shows the 
results of the model using adherence level as interval scaled 
variable, which tested the statistical significance of the trends. 
A significant decreasing trend in the log-odds of hospitaliza-
tion by adherence level could be observed in all treatment 
groups (Table 5; P,0.001). This linear trend is displayed by 
thin lines in Figure 2. For the patients treated with insulin, 
the ORs for hospitalization decreased with each additional 
level of adherence by a factor of 0.87 (95% CI: 0.81–0.94). 
Accordingly, the decrease of the ORs was 0.93 (95% CI: 
Table 2 Adherence to recommended diabetes care guidelines by drug treatment group
Measure of adherence (2011) Total Users of  
oral OAs
Users of 
insulin
Users of OAs and  
insulin in combination
P-valuea
% % % %
Performance measures
annual hba1c measurement 87.6 86.6 87.3 91.8 ,0.001
Annual lipid profile
annual total cholesterol test 65.2 66.6 58.3 64.2 ,0.001
annual hDl cholesterol test 56.5 57.5 52.1 55.9 ,0.001
annual lDl cholesterol test 19.8 19.9 19.0 20.1 0.317
Annual triglycerides test 59.0 60.0 54.0 58.5 ,0.001
Annual lipid profile (total cholesterol/HDL/LDL, and triglycerides) 59.0 59.9 54.0 58.3 ,0.001
annual nephropathy status
annual serum creatinine test 77.4 76.7 76.6 80.6 ,0.001
annual albuminuria test 13.1 11.6 17.0 16.6 ,0.001
Annual nephropathy status (serum creatinine and albuminuria) 12.0 10.6 15.5 15.4 ,0.001
Annual visit to an ophthalmologist 44.2 41.2 51.4 51.5 ,0.001
Adherence level
Nonadherent (level 0) 29.9 32.9 27.0 20.1 ,0.001
$2 hba1c measurements in a year (level 1) 24.0 22.3 27.3 28.7
Level 1 and annual lipid profile (level 2) 37.0 37.1 33.7 39.1
Level 2 and nephropathy status (level 3) 4.3 4.1 4.3 5.0
Level 3 and visit to an ophthalmologist (level 4) 4.8 3.7 7.7 7.2
Note: aP-values refer to chi-square test across the drug treatment groups.
Abbreviations: hba1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OAs, oral antidiabetic agents.
Table 3 Proportion of patients hospitalized in 2013 by adherence level and drug treatment in 2011
Hospitalization (2013)
Total Users  
of OAs
Users of 
insulin
Users of OAs and insulin 
in combination
P-valuea
% % % %
Adherence level (2011)
Nonadherent (level 0) 32.7 35.3 32.2 24.9 ,0.001
$2 hba1c measurement in a year (level 1) 26.9 25.0 29.6 30.9
Level 1 and annual lipid profile (level 2) 33.6 33.7 29.6 36.3
Level 2 and nephropathy status (level 3) 3.2 3.2 2.9 3.4
Level 3 and visit to an ophthalmologist (level 4) 3.6 2.8 5.7 4.5
Note: aP-values refer to chi-square test across the drug treatment groups.
Abbreviations: hba1c, hemoglobin A1c; OAs, oral antidiabetic agents.
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0.90–0.97) among patients treated with OAs and 0.84 (95% 
CI: 0.79–0.90) among those treated with OAs and insulin in 
combination. When comparing the trends between the treat-
ment groups, the effect of adherence on the hospitalization 
risk was strongest in patients treated with OAs and insulin 
in combination. However, the effect in this treatment group 
is only significantly greater than the effect of the treatment 
group with OAs only (P=0.002). The other two differences 
in trends were not significantly different.
Discussion
Our study revealed four findings. First of all, physicians’ 
guideline adherence, reflected by a simple set of performance 
measures was quite low. Second, adherence increased with 
a more intensified therapy and severity of diabetes. Third, 
guideline adherence predicted the risk of hospitalization. 
And finally, the effect size of the association between 
adherence and hospitalization risk depended on the therapy 
intensity.
Surprisingly, only a small percentage of patients (5%) 
were exposed to full adherence including the performance 
of all recommended process measures. About 30% of 
patients were considered as exposed to nonadherence and 
did not receive at least a biannual HbA
1c
 measurement. 
These results are consistent with prior research, which 
highlighted the poor guideline adherence in diabetes care, 
especially in the case of the HbA
1c
 measurement as the 
most important measure in the diabetes management.15,16 
Results from an US study showed that only 70% of patients 
with diabetes received an annual HbA
1c
 measurement and 
a large cohort study from Luxembourg reported that even 
55% of patients had no HbA
1c
 test within a year.15,16 Fur-
thermore, our study revealed a poor adherence with 20% 
in the measurement of LDL cholesterol, which is classified 
as an essential parameter in testing lipid profile in national 
Table 5 Prediction of hospitalization by adherence level 
(as interval scaled variable), including the interaction term 
“adherence level-drug treatment group” and adjusting for 
multiple comparisons
Hospitalization (2013) by 
Adherence level (2011)
ORa 95% CI
Drug treatment group
insulin 0.87b 0.81–0.94
Oas 0.93b 0.90–0.97
Oas and insulin in combination 0.84b 0.79–0.90
Oas vs insulin 1.07 0.98–1.16
Oas and insulin in combination vs insulin 0.96 0.87–1.06
Oas and insulin in combination vs Oas 0.90c 0.84–0.97
Notes: aAdjusted for all variables in Table 1; bP#0.001; cP#0.01.
Abbreviations: CI, confidence interval; OAs, oral antidiabetic agents; OR, 
odds ratio.
Figure 2 Odds ratios of hospitalization as a function of adherence level by treatment 
group.
Note: The thin lines represent the linear trend.
Abbreviations: OAs, oral antidiabetic agents; OR, odds ratio.
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Table 4 Prediction of hospitalization by adherence level (as factor variable), including the interaction term “adherence level-drug 
treatment group” and adjusting for multiple comparisons
Hospitalization (2013)
Users of insulin Users of oral OAs Users of OAs  
and insulin in  
combination
ORa 95% CI ORa 95% CI ORa 95% CI
Adherence level (2011)
Nonadherent (level 0) 1.00 (reference) 0.55 0.45–0.66 0.94 0.74–1.20
$2 hba1c measurement in a year (level 1) 0.88 0.69–1.13 0.55
d 0.45–0.67 0.78c 0.62–0.97
Level 1 and annual lipid profile (level 2) 0.74b 0.58–0.94 0.48d 0.40–0.58 0.70d 0.57–0.87
Level 2 and nephropathy status (level 3) 0.57c 0.34–0.96 0.47d 0.35–0.62 0.54d 0.36–0.83
Level 3 and visit to an ophthalmologist (level 4) 0.64c 0.43–0.95 0.39d 0.29–0.53 0.43d 0.30–0.63
Notes: aAdjusted for sociodemographics, health insurance status, hospitalization, use of antihypertensive drugs, and use of lipid lowering drugs; bP#0.01; cP#0.05; dP#0.001.
Abbreviations: CI, confidence interval; HbA1c, hemoglobin A1c; OAs, oral antidiabetic agents; OR, odds ratio.
Patient Preference and adherence 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
229
guideline adherence predicts hospitalization
as well as in international recommendations in diabetes 
care.4,17 Previous studies from Switzerland also suggested 
a suboptimal performance of HbA
1c
 measurement and lipid 
profile assessment, but showed higher adherence levels in 
lipid profile assessment than in our study. Bovier et al,18 
reported HbA
1c
 measurements three times a year for 65% 
and a yearly lipid profile assessment for 89% in a diabetes 
sample of 400 patients in the French-speaking part of Swit-
zerland. A further study showed that 84% had a biannual 
HbA
1c
 measurement among HbA
1c
 aware patients and 94% 
had undergone a lipid profile assessment.19 However, com-
parability to our findings is limited since previous studies 
were based on patients’ self-reporting, older data, or on 
selected medical files of a small diabetes sample and not on 
a large general population of persons with diabetes. Most 
patients achieved only adherence level 2 including at least 
two HbA
1c
 measurements and a lipid profile assessment. 
The proportion of patients with an additional nephropathy 
status (level 3) and ophthalmologist consultation (level 4) 
decreased significantly.
Therapy intensity, reflected in an additional insulin 
therapy or insulin therapy only was associated with an 
increased guideline adherence: we found the highest pro-
portion of patients receiving care according to level 4 (full 
adherence) in insulin users, followed by those with combined 
therapy (OA agents and insulin). We suppose that with 
increased disease severity, reflected in an intensified therapy, 
physicians’ awareness and therefore guideline adherence 
increased.
The major finding of our study is that it provides evidence 
that the adherence to medical standards in diabetes care led 
to a significantly decreased probability of future hospital-
ization among patients. An interaction between adherence 
levels and drug treatment group was found showing different 
trends for the treatment groups. The hospitalization risk for 
the treatment group with OAs was for low adherence levels 
considerably smaller than for the other two treatment groups. 
The effect size of the association between adherence and 
hospitalization risk was significantly stronger in the OAs 
group compared with the treatment group with OAs and 
insulin in combination. The association between adherence 
to guidelines and reduced rates of hospitalization was also 
found in the study by Sloan et al.11 Only few comparable 
population-based studies examining the impact of adherence 
to medical standards on outcomes such as hospitalization 
are available, particularly those using performed process 
measures as indicator for the adherence to guidelines. Most 
studies predicting health outcomes such as hospitalization or 
mortality are focused on oral antihyperglycemic medication 
adherence.20–23
In this context, it is important to acknowledge that 
guideline adherence in our study was defined by simple 
performance measures. Our results suggest that even this 
simple measurement, which could be easily calculated from 
health care claims data, is able to predict outcomes such as 
hospitalization. In Switzerland – as in many countries – there 
is a huge discussion on how to measure quality of care in 
ambulatory care. Our results suggest that already available 
datasets could help to reflect quality of care and therefore 
help to improve it.
Several strengths and limitations of our study have to 
be taken into account. The main strength is that the study 
was based on very comprehensive health care claims data, 
which covers a large population-based cohort of patients with 
diabetes. Health care claims data are a reliable and practice-
based information source, and they are particularly valuable 
when data from population-based disease studies are lacking. 
Our findings confirm that claims-based adherence measures 
are good indicators to determine patients’ health care behav-
ior and are additionally valuable predictors for health care 
utilization. The study also has several limitations. First, the 
number of patients with diabetes may be biased, because 
clinical diagnoses (eg, ICD-10) were not available, and 
undiagnosed patients without medication but with lifestyle 
treatment could not be included in the study. However, we 
assume that this potential bias is negligible, since diagnoses 
based on dispensed drugs are a valid proxy for clinical diag-
noses and in the meanwhile widely used in epidemiological 
and outcomes research to estimate diabetes prevalence.24,25 
Second, since we used the World Health Organization ATC 
codes to identify patients with diabetes, we were unable to 
distinguish between type 1 and type 2 diabetes. However, 
according to epidemiological data, it is assumed that ~90% 
of patients with diabetes were classified with type 2 diabetes. 
Moreover, since patients with type 1 diabetes are mostly 
younger persons (#18 years), and we included only adult 
patients, the majority of our study sample most likely com-
prised patients with type 2 diabetes.26 Third, the used data 
did not allow us to investigate long-term effects of poor 
adherence on health outcomes, thus it would be clinically 
important to examine a longer observation period in future 
studies. Fourth, our data did not include further information 
on clinical parameters such as laboratory values, duration 
of diabetes, and cardiovascular risk factors (ie, blood pres-
sure and body weight). Although our analysis was adjusted 
for numerous variables indicating patients’ disease severity 
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(kind of drug treatment) or comorbidities (eg, using drugs 
for hypertension), our information on the severity of diabetes 
and the overall health status is limited. A poor health status 
can act as confounder in our analyses. Since the frequency 
of health care use strongly depends on the disease severity, 
an underestimation of the positive impact on guideline 
adherence cannot be excluded. Fifth, the analyses criteria 
were process indicators and not intermediate ones. Guide-
line adherence has therefore to be considered as a proxy for 
better care in terms of better communication, education, or 
methodological approach. Finally, according to the given 
cohort study design, we had to exclude dead or ineligible 
persons from the study population. Therefore, the impact of 
guideline adherence and hospitalization risk applies only to 
persons who survive long enough to measure the adherence 
and its potential effect on future outcomes.
Conclusion
This study showed that health care claims data can be used 
to calculate a simple set of performance measures to observe 
adherence of provided care to established guideline recom-
mendations. Furthermore, a clear relation between adher-
ence levels and the hospitalization probability of diabetes 
patients could be proven. Regarding the low performance 
in the observed measures, our study emphasizes the need to 
foster the implementation of evidence in daily treatment of 
diabetes patients. Simple measures provided in this study 
seem to be able to enable this.
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